MedCAD's AccuStride receives FDA clearance

MedCAD, a Dallas-based company, has achieved a significant milestone with its AccuStride® system. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its innovative lower leg solution, specifically targeting the tibia and fibula regions. This clearance enables the production of patient-specific implants, marking a notable advancement in orthopedic medical technology. The AccuStride® system is designed to provide customized treatment options for patients requiring interventions in this complex anatomical area, potentially improving surgical outcomes and patient recovery.